Hims & Heiss remain blood-gypsies, leaf tests with Trybe-Deal
Hims & Hers Health Announced on Wednesday that it took over the laboratory test facility in New Jersey based in New Jersey.
The deal enables the Telemealth company to offer its users blood streets and more comprehensive pretreatment tests at home.
“Access to richer data enables us to deepen the findings that providers can use on our platform to guide your clinical decisions for each individual patient,” said Dr. Patrick Carroll, Chief Medical Officer from Hims & Hers.
“Laboratory tests at home are another exciting step to improve the personal, comprehensive nursing customers in this country,” added Dr. Carroll added.
Hims & Her has not announced the conditions of the deal, but said that it financed it through bar at hand. The company announced CNBC that the pricing for the new test options would issue if the offer will be made available to customers next year.
The acquisition by HIMS & HULS offers a competition for blood -drained such as Labcorp and Quest Diagnostics.
The startup extends its services by less than a year after offering weight loss medication with weight loss of GLP-1. When HIMS & HER throws itself as a cheaper alternative to established companies, it has recently been aimed at a Super Bowl display on the pharmaceutical industry and said that the industry was “for profits, not for patients”.
“The health care that customers expect today and earn today is the care of which with treatments that have been specially developed for them,” said Dr. Carroll.
While the company of the company was Volatil, Wall Street bought this year. The stocks rose by 141% in 2025 when they were trading on Tuesday. The stock rose more than 20% on Wednesday after the announcement of deal.
The new acquisition will add test functions for LDL cholesterol, lipoprotein (a), cholesterol and apolipoprotein, according to the company. It will also expand the company's ability to offer access and treatments over a number of diseases, including low testosterone and perimenopausal and menopause support.
The Tasso+ device is a blood lance that collects entire liquid blood samples.
With kind permission: Tasso Inc.
HIMS & HERS users receive a blood lance with Home Diagnostic Testing Company Tasso. The Lancet is a disposable device that collects entire liquid blood samples and is deleted for the use of Premarket by the US Food and Drug Administration.
Users attach the device to your upper arm and press a button that triggers the lancet to sting the skin and draw a small amount of blood collected in a microtube.
Providers on the platform use the information that was collected as part of a treatment plan for patients.
HIMS & HERS said that data from the blood test will be used to use patient identities-to accelerate the development of artificial intelligence health care.
Clarification: This story has been updated in order to reflect that the new test services will support the company's perimenopausal care.
